Roche Sticking With SMA Despite Terminating Olesoxime
Problems over formulation and the arrival of effective treatment options in spinal muscular atrophy, headed by Biogen's antisense oligonucleotide drug Spinraza, have led to the plug being pulled on olesoxime - but the Swiss major has a back-up candidate.
You may also be interested in...
Biogen's SMA Ambitions Run Up Against A New Deep-Pocketed Rival
Novartis' decision to buy gene therapy developer AveXis will have a crossover impact on Biogen, an early leader in the treatment market for spinal muscular atrophy (SMA) with Spinraza.
Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition
The Swiss major has made a larger-than-expected bolt-on buy, using a large chunk of its $13bn windfall from GSK to get hold of a potential cure for spinal muscular atrophy and an additional gene therapy platform, as well as manufacturing capabilities.
Deal-happy Roche acquires Trophos
In yet another deal, Roche is acquiring rare disease drug developer Trophos at a price of €120m upfront, and a further €350m in potential milestone payments.